{"product_id":"mygn-vrio-analysis","title":"Myriad Genetics, Inc. (MYGN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Myriad Genetics, Inc. (MYGN)'s competitive edge with this distilled VRIO analysis. We cut straight to the core, examining the Value, Rarity, Inimitability, and Organization of their key assets to reveal the true source of their market strength, as summarized in \u0026amp;O4\u0026amp;. Read on immediately to grasp the critical factors that define their success and what it means for their future performance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 1. Hereditary Cancer Testing Leadership \u0026amp; Brand Equity\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core engine of Myriad Genetics, Inc., and it’s clear that their Hereditary Cancer Testing (HCT) franchise remains the bedrock of their financial story, even as they push into other areas. The takeaway here is that this market position is a significant, likely sustained, competitive advantage, provided they keep innovating, like with their Precise MRD test.\u003c\/p\u003e\n\n\u003cp\u003eThe value generated by this leadership is tangible. For instance, in the second quarter of fiscal year 2025, Myriad Genetics’ Oncology HCT revenue grew by a solid \u003cstrong\u003e9%\u003c\/strong\u003e year-over-year, with test volumes up \u003cstrong\u003e10%\u003c\/strong\u003e. That’s not just noise; that’s real dollars flowing from established clinical workflows. To be fair, the unaffected population segment saw slower growth, with revenue up only \u003cstrong\u003e1%\u003c\/strong\u003e, but the high-value oncology segment is clearly pulling the weight. Also, look at the MyRisk with RiskScore test specifically - its volume jumped \u003cstrong\u003e14%\u003c\/strong\u003e YoY in Q2 2025, showing adoption of their more advanced risk stratification tools.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO dimensions for this core asset:\u003c\/p\u003e\n\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eSupporting Data (FY2025)\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eQ2 2025 Oncology HCT Revenue Growth: \u003cstrong\u003e9%\u003c\/strong\u003e YoY; MyRisk with RiskScore Volume Growth: \u003cstrong\u003e14%\u003c\/strong\u003e YoY.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eSustained leadership in the established hereditary cancer testing niche is uncommon among diagnostics peers.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eHigh Imitation Cost\u003c\/td\u003e\n    \u003ctd\u003eDecades of clinical adoption, payer coverage, and physician trust are difficult and slow to replicate.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eOrganized to Exploit\u003c\/td\u003e\n    \u003ctd\u003eActively leveraging HCT leadership to expand across the Cancer Care Continuum (CCC), including MRD testing.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n    \u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eThe combination of value, rarity, and high imitation cost suggests durability.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRarity comes from the sheer duration of their presence. When a clinician reaches for a hereditary cancer test, Myriad Genetics is often the first name that comes to mind, a form of cognitive lock-in that new entrants struggle to break. What this estimate hides is the pressure from next-generation sequencing competitors and the evolving reimbursement landscape, which could erode the value over time if Myriad doesn't keep pushing the science forward.\u003c\/p\u003e\n\n\u003cp\u003eThe organization seems aligned to capitalize on this strength. Management is explicitly using this foundation to drive expansion into adjacent, high-growth areas within the CCC. For example, in the third quarter of 2025, the company reported a collaboration with SOPHiA GENETICS to develop a liquid biopsy companion diagnostic (CDx) testing solution, directly linking their oncology expertise to new therapeutic monitoring markets. This shows they aren't resting on their laurels.\u003c\/p\u003e\n\n\u003cp\u003eTo keep this advantage sustained, we need to see continued momentum. While Q2 2025 was strong, Q3 2025 showed HCT revenue growth slowing to \u003cstrong\u003e3%\u003c\/strong\u003e YoY overall, though volume was up \u003cstrong\u003e11%\u003c\/strong\u003e YoY, suggesting pricing or mix was less favorable that quarter. We need to track if the Q2 performance was an anomaly or if the Q3 slowdown is the new normal.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOncology HCT Volume (Q2 2025): \u003cstrong\u003e10%\u003c\/strong\u003e YoY increase.\u003c\/li\u003e\n\u003cli\u003eUnaffected Population Volume (Q3 2025): \u003cstrong\u003e11%\u003c\/strong\u003e YoY increase.\u003c\/li\u003e\n\u003cli\u003ePrecise MRD test data presented at ASCO in May 2025.\u003c\/li\u003e\n\u003cli\u003eAI-driven prostate test launch planned for Q1 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: Re-run the DCF sensitivity analysis using a \u003cstrong\u003e3%\u003c\/strong\u003e HCT revenue growth rate for the next two quarters to model the downside risk.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 2. Proprietary Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects key diagnostic methods and gene discoveries, forming the foundation for current and future tests.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate to High; foundational patents on genes like BRCA are unique, though some may be expiring. Following the 2013 Supreme Court decision, Myriad retained more than 500 valid and enforceable claims in 24 different patents conferring strong patent protection for its BRACAnalysis® test.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; patent protection legally prevents direct imitation for a set period.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is focused on extending the value of existing patents through R\u0026amp;D investment in 2025. Full-year 2024 revenue was $838 million. Adjusted operating expenses in the fourth quarter of 2024 increased $16.0 million year-over-year, reflecting increased spending on clinical studies to support the development and launches of Precise MRD and other research and development expense during the fourth quarter 2024. Third quarter 2025 Adjusted operating expenses were $140.0 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained\u003c\/p\u003e\n\u003cp\u003eRecent Intellectual Property and Financial Context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Period\u003c\/th\u003e\n\u003cth\u003eContext\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patents Post-2013 Decision\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\u0026gt;500\u003c\/strong\u003e Claims in \u003cstrong\u003e24\u003c\/strong\u003e Patents\u003c\/td\u003e\n\u003ctd\u003eConferring strong protection for BRACAnalysis® test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents Granted in \u003cstrong\u003e2024\u003c\/strong\u003e (MRD)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e Patents\u003c\/td\u003e\n\u003ctd\u003eRelated to foundational platform MRD technology and cell-free DNA preparation methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents Granted in \u003cstrong\u003e2025\u003c\/strong\u003e (YTD Feb)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e New Patents\u003c\/td\u003e\n\u003ctd\u003eFurther advancing the Precise MRD assay.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year \u003cstrong\u003e2024\u003c\/strong\u003e Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$838 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContext for overall business scale.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 \u003cstrong\u003e2024\u003c\/strong\u003e R\u0026amp;D Expense Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year increase in Adjusted operating expenses reflecting R\u0026amp;D spending.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 \u003cstrong\u003e2025\u003c\/strong\u003e Adjusted Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$140.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflecting disciplined cost management and strategic investments.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific recent patent grants include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eU.S. patent no. \u003cstrong\u003e12,104,212\u003c\/strong\u003e, granted in October 2024, covering proprietary methods for detecting circulating tumor DNA (ctDNA).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePatent number: \u003cstrong\u003e12,221,656\u003c\/strong\u003e, with a Date of Patent: February 11, 2025, for methods and materials for assessing homologous recombination deficiency (HRD).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePatent number: \u003cstrong\u003e12,410,478\u003c\/strong\u003e, with a Date of Patent: September 9, 2025, related to molecular markers for cancer predisposition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 3. Clinical Validation \u0026amp; Evidence Base\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the necessary data for payer coverage and physician adoption, crucial for test reimbursement.\u003c\/p\u003e\n\u003cp\u003eThe evidence base directly supports revenue generation through favorable coverage decisions. Full-year 2024 total revenues reached approximately \u003cstrong\u003e$838 million\u003c\/strong\u003e. Third quarter 2024 revenue grew \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year, driven in part by progress on payor coverage initiatives. Second quarter 2024 revenue grew \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many competitors have validation, but Myriad’s historical depth is significant.\u003c\/p\u003e\n\u003cp\u003eMyriad’s historical data generation, particularly for BRCA1\/2, is a significant differentiator. By Myriad’s count, some \u003cstrong\u003e18,000 researchers\u003c\/strong\u003e published \u003cstrong\u003e8,000 papers\u003c\/strong\u003e from BRCA1\/2-related studies conducted after Myriad's gDNA patents were issued. The company continues to publish additional clinical validation studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires long-term, expensive, peer-reviewed study execution.\u003c\/p\u003e\n\u003cp\u003eThe scale of historical data collection and ongoing study execution represents a barrier. The company's gross margin in Q4 2024 was \u003cstrong\u003e71.7%\u003c\/strong\u003e, indicating the high value captured from these established tests, which underpins the investment in evidence generation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the strategy is explicitly clinical evidence and guideline driven.\u003c\/p\u003e\n\u003cp\u003eThe product portfolio is strategically aligned with established clinical standards. Myriad's full suite of prostate cancer products is uniquely aligned with the updated \u003cstrong\u003eNCCN Guidelines\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\n\u003cp\u003eKey metrics illustrating the impact of clinical validation and evidence on market access:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Context\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Source Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$838 million\u003c\/strong\u003e (approx.)\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight Revenue from UNH (TTM)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$40 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTrailing Twelve Months ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates with Biomarker Legislation Passed (GeneSight)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15 states\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRCA1\/2 Related Studies Published (Post-Patent)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,000 papers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHistorical Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2024 GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eProgress in securing favorable coverage is evident through specific business segment performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThird quarter 2024 GeneSight testing revenue grew \u003cstrong\u003e34%\u003c\/strong\u003e year-over-year, reflecting ongoing initiatives to improve payor coverage.\u003c\/li\u003e\n\u003cli\u003ePrenatal testing revenue in Q2 2024 grew \u003cstrong\u003e25%\u003c\/strong\u003e year-over-year, reflecting expanded coverage by payers.\u003c\/li\u003e\n\u003cli\u003eHereditary cancer testing volumes in Women's Health grew \u003cstrong\u003e10%\u003c\/strong\u003e year-over-year in Q4 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 4. Operational Excellence \u0026amp; Laboratory Efficiency\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eEnables a leading gross margin profile, with GAAP Gross Margin reported at \u003cstrong\u003e71.2%\u003c\/strong\u003e in Q2 2025, reflecting operating leverage and improved average revenue per test.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Q2 2025)\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp over 160 basis points year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$213.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGAAP revenue growth of 1% year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Operating Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp approximately 16% from Q2 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHereditary Cancer Test Volume Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflecting operational execution within Oncology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate; high margins are rare in diagnostics, but operational excellence is a common goal.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate; efficiencies gained through process refinement are hard to copy exactly. Specific, measurable improvements in laboratory and administrative processes demonstrate this focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDocument classification accuracy increased from \u003cstrong\u003e94%\u003c\/strong\u003e to \u003cstrong\u003e98%\u003c\/strong\u003e using optimized generative AI models.\u003c\/li\u003e\n\u003cli\u003eProcessing costs for document classification decreased by \u003cstrong\u003e77%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProcessing latency for documents decreased from \u003cstrong\u003e8.5 minutes\u003c\/strong\u003e per document to \u003cstrong\u003e1.3 minutes\u003c\/strong\u003e per document.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eHigh; management emphasizes operational excellence to fund growth.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFull-year 2025 Gross Margin guidance raised to \u003cstrong\u003e69.5%-70.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-year 2025 Adjusted EBITDA guidance raised to \u003cstrong\u003e$27 million to $33 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNew COO appointed effective April 30, 2025 (Mark S. Verratti promoted from CCO).\u003c\/li\u003e\n\u003cli\u003eMulti-year program announced to invest over \u003cstrong\u003e$35 million\u003c\/strong\u003e in commercial capabilities addressing the Cancer Care Continuum.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eTemporary\u003c\/p\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 5. Commercial Infrastructure \u0026amp; Physician Reach\u003c\/h2\u003e\n\u003cp\u003eThe commercial infrastructure supports the delivery and adoption of Myriad's genetic testing portfolio across the U.S. healthcare system.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe infrastructure includes a U.S. sales force comprised of approximately \u003cstrong\u003e500 individuals\u003c\/strong\u003e as of February 2024. This reach facilitates test ordering and adoption across specialties, evidenced by adding over \u003cstrong\u003e4,000 clinicians\u003c\/strong\u003e who ordered GeneSight for the first time in the fourth quarter of 2023.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eBuilding and maintaining a specialized sales force of this scale requires significant capital investment and time. The company achieved a full-year 2023 revenue of \u003cstrong\u003e$753 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eWhile competitors can hire sales representatives, establishing the depth of relationships and market penetration achieved through sustained effort is time-consuming. The company demonstrated continued growth driven by this infrastructure, with first quarter 2024 revenue growing \u003cstrong\u003e12%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eOrganizational focus supports this infrastructure through initiatives like EMR integrations designed to serve patients seamlessly and efficiently. The organization's performance reflects this structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst quarter 2024 test volumes were \u003cstrong\u003e381,000\u003c\/strong\u003e, a \u003cstrong\u003e9%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eThird quarter 2024 revenue grew \u003cstrong\u003e11%\u003c\/strong\u003e compared to the third quarter of 2023.\u003c\/li\u003e\n\u003cli\u003eFourth quarter 2024 GAAP gross margin was \u003cstrong\u003e71.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe impact of the commercial infrastructure on recent financial performance is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ4 2023\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-Year Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e11%\u003c\/strong\u003e (Full Year 2023 Revenue: \u003cstrong\u003e$753 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Test Volumes (Approx.)\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e360,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e381,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew GeneSight Clinicians Added\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e4,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; the combination of the established sales force size (approx. \u003cstrong\u003e500\u003c\/strong\u003e U.S. reps) and demonstrated ability to drive adoption (e.g., \u003cstrong\u003e21%\u003c\/strong\u003e GeneSight volume growth in Q4 2023) provides a competitive moat.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 6. Electronic Medical Records (EMR) Integration Capability\n\u003c\/h2\u003e\n\u003cp\u003eThe capability for Electronic Medical Records (EMR) integration is a key operational driver for Myriad Genetics' commercial execution.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment Driver\/Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDirect driver of test volume via workflow embedding\u003c\/td\u003e\n\u003ctd\u003eEMR improvements supported MyRisk HCT growth in the affected population.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eIndustry adoption status\u003c\/td\u003e\n\u003ctd\u003eEMR integration is a focus area for the company.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eRequirements for replication\u003c\/td\u003e\n\u003ctd\u003eRequires specific IT investment and provider partnerships. [cite: 2 (implied by context of EMR improvements)]\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eQuantifiable impact on performance\u003c\/td\u003e\n\u003ctd\u003eDirectly contributed to \u003cstrong\u003e14%\u003c\/strong\u003e volume growth for MyRisk HCT in oncology in Q2 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther statistical context from Q2 2025 results:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHereditary Cancer Testing (HCT) in Oncology volume grew \u003cstrong\u003e10%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eMyRisk with RiskScore testing volume in oncology grew \u003cstrong\u003e14%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eHereditary cancer testing revenue for the unaffected population increased \u003cstrong\u003e1%\u003c\/strong\u003e, with volume up \u003cstrong\u003e3%\u003c\/strong\u003e year-over-year, as the company deploys EMR solutions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's overall Q2 2025 revenue was reported at \u003cstrong\u003e$213.1 million\u003c\/strong\u003e, with underlying revenue growth of \u003cstrong\u003e5%\u003c\/strong\u003e when excluding certain headwinds. The company raised its full-year 2025 revenue guidance to a range of \u003cstrong\u003e$818 - $828 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 7. Pipeline of Next-Generation Oncology Tests\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positions the company for future revenue streams beyond current core offerings, like AI-enabled Prolaris and MRD tests.\u003c\/p\u003e\n\u003cp\u003eThe Prolaris test demonstrated revenue growth of \u003cstrong\u003e3%\u003c\/strong\u003e year-over-year in the third quarter of 2025, while hereditary cancer testing revenue in Oncology grew \u003cstrong\u003e3%\u003c\/strong\u003e year-over-year in the same period, with volume increasing by \u003cstrong\u003e11%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eNext-Generation Test\u003c\/td\u003e\n\u003ctd\u003eKey Milestone\/Event\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003ctd\u003eAssociated Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled Prolaris Test (PATHOMIQ partnership)\u003c\/td\u003e\n\u003ctd\u003eIntended Commercial Launch\u003c\/td\u003e\n\u003ctd\u003eFirst half of 2026\u003c\/td\u003e\n\u003ctd\u003eN\/A (Future Revenue Stream)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecise MRD Test\u003c\/td\u003e\n\u003ctd\u003eClinical Data Presentation (MONSTAR-SCREEN 3)\u003c\/td\u003e\n\u003ctd\u003eMay 2025 (ASCO)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e sensitivity at baseline reported in study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecise MRD Test\u003c\/td\u003e\n\u003ctd\u003eClinical Data Presentation\u003c\/td\u003e\n\u003ctd\u003eApril 2025 (AACR)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Data Presentation)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; several competitors are also developing advanced oncology tools.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the specific AI integration and proprietary MRD assay are unique developments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; R\u0026amp;D investment is maintained to support these planned 2026 launches.\u003c\/p\u003e\n\u003cp\u003eResearch and Development Expense figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFor the nine months ended September 30, 2025: \u003cstrong\u003e$81.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the year ended December 31, 2024: \u003cstrong\u003e$113.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the first quarter of 2025: \u003cstrong\u003e$27.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe Research and development expense as a percentage of total revenue for the year ended December 31, 2024, was \u003cstrong\u003e13.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 8. Diversified Diagnostic Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Mitigates risk from single-product reliance or payer coverage changes (e.g., Prenatal revenue grew \u003cstrong\u003e11%\u003c\/strong\u003e in Q1 2025). The diversification across Women's Health, Oncology, and Pharmacogenomics provides revenue stability, evidenced by Prenatal revenue reaching \u003cstrong\u003e$55 million\u003c\/strong\u003e in Q1 2025, offsetting a \u003cstrong\u003e20%\u003c\/strong\u003e year-over-year decline in Pharmacogenomics revenue due to payer coverage changes in the same period. Total Q1 2025 revenue was \u003cstrong\u003e$196 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; most large players have multiple test categories. Myriad's portfolio includes Hereditary Cancer, Tumor Profiling, Prenatal, Pharmacogenomics, and Autoimmune testing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors can acquire or develop tests in Women's Health or Mental Health. Competitors can acquire existing platforms or develop comparable tests in areas like Hereditary Cancer (MyRisk) or Prenatal (Prequel).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is executing on a strategy focused on the CCC, which implies portfolio integration. The company is prioritizing investment in new product development while taking steps to reduce overall expenditures following the Q1 2025 results.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None\u003c\/p\u003e\n\u003cp\u003eThe Q1 2025 segment performance illustrates the mixed impact of portfolio diversification:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostic Segment\/Metric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Revenue\/Volume\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$196 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-3%\u003c\/strong\u003e (or \u003cstrong\u003e5%\u003c\/strong\u003e excluding headwinds)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrenatal Testing Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacogenomics (GeneSight) Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$77.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMixed (Hereditary Cancer Revenue -\u003cstrong\u003e2%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Test Volume\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e385,000\u003c\/strong\u003e tests\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e40\u003c\/strong\u003e basis points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey components contributing to the portfolio's breadth include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHereditary Cancer testing, with MyRisk® testing volume in the affected population growing \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year in Q1 2025.\u003c\/li\u003e\n\u003cli\u003ePrenatal testing, which saw positive early adoption of the Prequel®Early Gestational Age test launched in Q4 2024.\u003c\/li\u003e\n\u003cli\u003ePharmacogenomics, which was significantly impacted by UnitedHealthcare discontinuing coverage of GeneSight®, leading to a \u003cstrong\u003e20%\u003c\/strong\u003e revenue decline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMyriad Genetics, Inc. (MYGN) - VRIO Analysis: 9. Financial Flexibility and Capital Access\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The new senior secured term loan credit facility provides up to \u003cstrong\u003e$200 million\u003c\/strong\u003e in capital, supplementing existing cash and cash equivalents to provide access to more than $200 million in total capital to support the growth strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; access to capital markets, including debt financing, is common for public companies, although specific terms vary based on credit profile and market conditions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors with comparable asset bases and market standing can also access debt markets to secure similar financing structures.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management secured this five-year facility on July 31, 2025, replacing the previous asset-based lending (ABL) facility to better support the updated growth strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft updated 13-week cash flow projection incorporating new credit facility terms by Friday.\u003c\/p\u003e\n\u003cp\u003eKey details of the new financing structure and recent liquidity metrics are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Facility Size\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$200 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnnounced July 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitially Funded Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$125 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional Borrowing Option\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$75 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUntil June 30, 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaturity Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJuly 31, 2030\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFive-year term loan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Rate Structure\u003c\/td\u003e\n\u003ctd\u003eSOFR plus \u003cstrong\u003e6.50%\u003c\/strong\u003e per year\u003c\/td\u003e\n\u003ctd\u003eSubject to a SOFR floor of \u003cstrong\u003e2.50%\u003c\/strong\u003e annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of end of Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$373 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAround July 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe facility is secured by substantially all assets of Myriad Genetics and its subsidiaries. The agreement includes specific financial maintenance covenants:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMinimum trailing twelve-month revenue test commencing December 31, 2025, at \u003cstrong\u003e$615 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe minimum revenue test increases quarterly to \u003cstrong\u003e$974 million\u003c\/strong\u003e beginning December 31, 2029, and thereafter.\u003c\/li\u003e\n\u003cli\u003eScheduled principal payment of \u003cstrong\u003e2.50%\u003c\/strong\u003e of unpaid principal due quarterly commencing September 30, 2029.\u003c\/li\u003e\n\u003cli\u003eFull-Year 2024 Revenue was \u003cstrong\u003e$838 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSecond Quarter 2025 Revenue was \u003cstrong\u003e$213.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516213256341,"sku":"mygn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/mygn-vrio-analysis.png?v=1740197235","url":"https:\/\/dcf-model.com\/fr\/products\/mygn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}